A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Summary

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

Timeline

Start

2025-03-13

Primary completion

2026-12-31

Completion

2027-06-30

Drugs

Indications